Restricted accessLetterFirst published online 2021-3
BMS,IMS,EMAS,RCOG and AMS joint statement on menopausal hormone therapy and breast cancer risk in response to EMA Pharmacovigilance Risk Assessment Committee recommendations in May 2020
National Institute for Health and Care Excellence. Menopause: diagnosis and management. London, UK: NICE, 2015.
3.
Collaborative Group on Hormonal Factors in Breast Cancer.
Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet2019;
394: 1159–1168.
4.
ChlebowskiRTAndersonGLAragakiAK, et al.
Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the women’s health initiative randomized clinical trials. JAMA2020;
324: 369–380.
5.
RossouwJEAndersonGLPrenticeRL, et al.
Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA2002;
288: 321–333.
6.
de VilliersTJHallJE, J. V.PinkertonJV, et al.
Revised global consensus statement on menopausal hormone therapy. Climacteric2016;
91: 153–155.
7.
BaberRJPanayN, andtheIMSWritingGroup.IMS recommendations on women’s midlife health and menopause hormone therapy. Climacteric2016;
19: 109–150.
8.
Marsden J, Pedder H and Santen R. British Menopause Society with acknowledgement to Professor Richard Santen. Risks and benefits of hormone replacement therapy before and after a breast cancer diagnosis. Post Reprod Health. Epub ahead of print 23 July 2020. DOI: 10.1177/2053369120934026
9.
Hamoda H, Panay N, Pedder H, et al. The British Menopause Society & Women’s Health Concern 2020 recommendations on hormone replacement therapy in menopausal women. Post Reprod Health 2020; 26(4): 181–209.
10.
The 2017 hormone therapy position statement of The North American Menopause Society.Menopause2018;
25: 1362–1387.
11.
FournierAMesrineSDossusL, et al.
Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort. Breast Cancer Res Treat2014;
145: 535–543.
12.
FournierABerrinoF andClavel-ChapelonF.Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat2008;
107: 103–111.
13.
AvisNECarolinaNCrawfordSL.Duration of menopausal vasomotor symptoms over the menopause transition. JAMA2015;
175: 531–539.
BoardmanHMHartleyLEisingaA, et al.
Hormone therapy for preventing cardiovascular disease in postmenopausal women. Cochrane Database Syst Rev2015;
3: CD002229.
16.
MansonJEAragakiAKRossouwJE, etal.
Menopausal hormone therapy and long-term all-cause and cause-specific mortality. JAMA2017;
318: 927–938.
17.
MansonJEAragakiAKBassukSS, et al.
Menopausal estrogen-alone therapy and health outcomes in women with and without bilateral oophorectomy: a randomized trial. Ann Intern Med2019;
171: 406–414.
18.
MikkolaTSTuomikoskiPLyytinenH, et al.
Estradiol-based postmenopausal hormone therapy and risk of cardiovascular and all-cause mortality. Menopause2015;
22: 976–983.
19.
SalpeterSRChengJThabaneL, et al.
Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women. Am J Med2009;
122: 1016–1022.e1.
20.
BeralVReevesGBullDGreenJ;
Million Women Study Collaborators. Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst2011;
103: 296–305.
21.
ZhuLJiangXSunY, et al.
Effect of hormone therapy on the risk of bone fractures: a systematic review and meta-analysis of randomized controlled trials. Menopause2016;
23: 461–470.
